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Introduction
Vitiligo is an idiopathic pigmentary disorder of the skin 
characterized by sharply demarcated asymptomatic 
depigmented macules. Its pathogenesis is still unclear. 
Many mechanisms and theories have been suggested 
including autoimmunity, auto cytotoxicity, biochemical 
and neuronal mechanisms.1 
No universally effective nor curative medical or 
surgical treatment has been proposed till this day. First 
line treatments include topical treatments such as 
corticosteroids and calcineurin inhibitors. While surgical 
options such as autologous melanocytes transplantation 
are suggested later on. Phototherapy, including narrow 
band ultraviolet B (NB-UVB) and monochromatic 
excimer light (MEL) of wavelengths 311 nm and 308 
nm respectively, is considered as a successful method 
of treatment among those approaches.2 The cytotoxic 
T-cells accountable for the destruction of melanocytes 
and disappearance of melanin are eliminated by 
phototherapy through apoptosis (diffuse repigmentation) 
and UVB does stimulate melanocytic proliferation and 
their migration to the epidermis from nearby follicular 
units (follicular repigmentation) and perilesional active 
melanocytes (marginal repigmentation).3 
NB-UVB indoor cabins have been used to treat vitiligo 
since the early 1990s, but recently, MEL was used and 
adapted for the treatment of some dermatological diseases 
including vitiligo.4 The 308 nm wavelength delivered 
by either laser/lamp has shown satisfactory superiority 
to broad band (BB-UVB) and NB-UVB for clinically 
treating vitiligo.5
Only few researchers studied histopathological changes 
before and after treatment with NB-UVB.6 However, 
to the best of our knowledge, none compared the 
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Abstract
Introduction: Recently, the monochromatic excimer light (MEL) of 308 nm wavelength 
has shown some advantages in comparison to narrow band ultraviolet B (NB-UVB) for the 
treatment of vitiligo. To histopathologically compare the early effects of NB-UVB and 308-
nm MEL phototherapy on vitiliginous patches using H&E and HMB-45. 
Methods: Thirty subjects with non-segmental vitiligo lesions were treated twice a week for 
6 weeks with 308-nm MEL, while NB-UVB was used to treat lesions contra laterally. Skin 
biopsies were taken from lesional areas before and after 6 weeks of treatment by either 
modality. It was prepared for light microscopy and immunohistochemical study (HMB-
45). This study was performed as a clinical trial (Trial registration: http://www.pactr.org; 
Identifier: PACTR201705002279419)
Results: All lesions before treatment had labeling index (number of pigmented cells/non-
pigmented cells) of 0.0 (0%). After treatment the LI for MEL was 4.2 ± 2.6, while for NB-
UVB LI it was 0.3 ± 0.7. MEL showed higher statistical significance regarding increase of 
basal pigmented cells, and significant decrease in vacuolated keratinocytes and basal 
membrane thickness than NB-UVB. 
Conclusion: Although NB-UVB is considered as treatment of choice for vitiligo, MEL is 
acknowledged as an effective treatment modality for vitiliginous lesions that induces more 
repigmentation than NB-UVB, and more rapidly, as confirmed by our study. 
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histopathological changes of lesions before and after 
treatment with MEL and NB-UVB. Therefore, the aim 
was to study the early effects of both MEL and NB-
UVB in vitiliginous lesions, histopathologically, using 
haematoxylin & eosin (H&E) and immunohistochemically, 
using human melanoma black-45 (HMB-45) stain.
Methods 
All Patients were asked to give full history in regards of 
medical history, disease duration, as well as family history 
of vitiligo. Assessment of the skin phototype was done 
according to Fitzpatrick’s classification.
 
Patients
Our study was conducted on 30 patients with nonsegmental 
vitiligo with at least 2 symmetrical vitiliginous patches. 
Their ages ranged from 18–60 years. We excluded 
patients with lesions located on sun exposed areas (for 
possible re-pigmentation), past history of dermatological 
cancer, photosensitivity disorders, immunosuppressive 
treatment, pregnancy and breastfeeding, phototherapy or 
topical treatment for the last 6 months prior to the study. 
Patients were enrolled from the dermatology out-patient 
clinic of the National Research Centre.
Treatment Plan 
Two symmetrical skin lesions were selected from each 
patient. One was treated with MEL and contra laterally 
with NB-UVB. During the NB-UVB session, areas 
already treated by MEL were covered to avoid dual 
exposure. Treatment sessions were given twice weekly on 
non-successive days for 6 weeks. For both treatments, the 
initial dose was almost 70% of the minimal erythematous 
dose (MED) calculated before treatment. Dose increases 
were 40% from treatment numbered 1 to 4, 30% from 4 to 
8, and 20% continuously from treatment 8 forwards, until 
slight erythema was attained. All patients were instructed 
to avoid any topical treatment. 
Phototherapy Sources 
NB-UVB was delivered using a Waldmann ramp 
equipped with 13 Philips®, TL 100W/01 fluorescent 
tubes (Waldmann Medizintechnik GmbH, Villingen-
Schwenningen, Germany) emitting 15 mW/cm2 at a 
distance of 20 cm, as measured by a Waldmann -UV 
Meter -dosimeter, and a TP4 Cosmedico (Technique 
Médicale, Otterswiller - Saverne, France).
A 308-nm xenon chloride MEL delivery system (Excilite®, 
Deka Mela, Florence, Italy) was used to irradiate skin 
with average power density of 50 mW/cm2 at a tube-to-
skin distance of 15 cm and with maximum rectangular 
irradiating area of 576c m2 (36 cm × 16 cm).
Biopsy Sampling
Three punch biopsies (5 mm each) were obtained from 
each patient. One at baseline from vitiliginous skin before 
starting therapy and one after 6 weeks of therapy from 
each of the NB-UVB and Excimer light treated areas.
Biopsies were fixated in 10% neutral buffered formalin, 
routinely processed, embedded in a paraffin block 
and sectioned by the ordinary microtome into five 
um thickness cut sections. The resultant sections were 
mounted on ordinary glass slides and positively charged 
slides to be subjected to conventional H&E stain and 
HMB-45 immunohistochemical stain.
Immunohistochemical Staining
Sections on the positively charged slides were prepared for 
immunohistochemical staining with HMB-45 according 
to the instructions provided by the manufacturer as 
follow: monoclonal mouse anti-human HMB-45 protein, 
which recognized the structural glycoprotein 100 
(gp100) associated to immature, premelanosomes-22, 
23 (monoclonal antibody, Dako Corp., Carpinteria, CA, 
USA, in dilution ratio of 1:50, code no: 364S207, USA) to 
demonstrate HMB-45 expression. Hematoxylin was used 
as a counter stain.
Histopathological Evaluation 
Light microscope with built-on camera (Olympus CX41, 
Germany) was used to examine and to photograph the 
H&E stained sections. Both dermal and epidermal layers 
were examined and reported. Based on to Anbar et al7 
work the following criteria were evaluated: vacuolated 
degenerated keratinocytes, basal pigmented cells, dermal 
edema and dermal perivascular inflammatory cells. 
Expression of the Marker 
HMB-45 normally stains the basal epidermal melanocytes, 
and the expression is cytoplasmic. The number of positive 
cells by HMB-45 monoclonal antibody were scored in 
each section using ×400 magnification in 10 high power 
fields and the percentage of melanocytes in relation to 
keratinocytes of the basal cell layer (labelling index) (LI).8 
The mean value of positive cells/HPF was then statistically 
analyzed in V, NB and MEL areas before and after 6 
weeks of therapy. Count of the number of the vacuolated 
keratinocytes, basal pigmented cells as well as the number 
of the stained cells were done in 5 random high power 
fields, counted on the screen using Leica Qwin 500 Image 
Analyzer (LEICA Imaging Systems Limited, Cambridge, 
England). 
Statistical Analysis
This analysis was conducted by the SPSS program, also 
known as the statistical program for social sciences for 
Windows.
For the parametric numeral data mean, 
standard deviation (±SD) and range were used. 
As for the non-parametric numerical data, frequency 
and percentage of non-numerical data: Median and 
interquartile range (IQR) were applied.
In assessing the statistical significance of the difference 
of an ordinal variable measured twice for the same 
study entity, the Wilcoxon signed rank test was applied. 
McNemar test was used to evaluate the statistical 
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significance of the difference between a qualitative 
variable measured for the same study entity. Paired t test 
was performed to consider the statistical significance of 
the difference between 2 means measured for the same 
study cluster. P value (the level of significance) was 
considered insignificant where it was higher than 0.05, P 
value of less than 0.05 is significant and P value less than 
0.01 is highly significant.
Results
Our study included thirty patients with non-segmental 
vitiligo. Their age was between 18 and 60 years old, with a 
mean ± SD of 32.5 ± 11.2 years. Three (10%) patients were 
classified as Fitzpatrick skin type II, 10 (33.3%) were skin 
type III, 12 (40%) were skin type IV and 5 (16.7%) were 
skin type V. In this study the disease duration amongst the 
patients was 6.4 ± 5.4 years with a minimum of 1 year and 
maximum of 19 years.
Starting dose for MEL treatment was 0.5±0.1 J/cm2, same 
as NB-UVB. On the other side the cumulative dose for 
MEL was 12.7 ± 2.5 J/cm2, while that for NB-UVB was 
15.5 ± 4.2 J/cm2. Repigmentation showed a superior 
statistical significance towards MEL in comparison to 
NB-UVB (P < 0.001).
Side effects from both modalities were in the form of 
erythema, xerosis and blistering. There was no superior 
significance to any treatment modality in regards to side 
effects (P > 0.05).
Hematoxylin & Eosin Staining Findings 
On comparing areas treated with MEL at baseline and after 
treatment histopathologically with H&E stain, there was 
a highly significant rise in the number of basal pigmented 
cells (P < 0.001) and a statistically significant shrinkage 
in basal membrane thickness and number of vacuolated 
keratinocytes (P < 0.05) after treatment. However, no 
statistically substantial changes were noted in dermal 
edema and perivascular inflammation. Meanwhile, 
post treatment with NB-UVB, showed non-significant 
changes in dermal edema, perivascular inflammation, 
vacuolated keratinocytes, basal membrane thickness and 
most importantly basal pigmented cells, which remained 
the same (Figures 1 and 2).
On comparing both MEL and NB-UVB as regards to the 
H&E findings, there was superior statistical significance 
for MEL against NB-UVB concerning basal membrane 
thickness, vacuolated keratinocytes and basal pigmented 
cells. There was no superiority to any modality regarding 
dermal edema and perivascular inflammation.
Immunohistochemistry Findings 
All vitiligo lesions before treatment with either NB-UVB 
or MEL had labelling index (LI) (number of pigmented 
cells/non pigmented cells) of 0.0 (0%). After treatment 
(starting eighth session), the labelling index (LI) for MEL 
was 4.2 ± 2.6 while for NB UVB LI was 0.3 ± 0.7, being 
more statistically significant for MEL modality (P < 0.001; 
Figure 3).
Discussion
The mechanisms by which UV light improve vitiliginous 
patches are still being studied, as no single theory has 
been proved to explain the exact pathogenesis. On the 
photo biological level, the wavelengths of 311-nm (NB-
UVB) and the 308-nm MEL are very similar to each other, 
and may share their therapeutic effects’ theories.9
Many studies proved the benefits of 308-nm MEL (laser/
lamp) over NB-UVB, regarding the relatively rapid onset 
of repigmentation, less treatment sessions required for 
repigmentation and lower cumulative doses.10
Figure 1. Biopsy Sample Before Treatment Labeled (V1, V2), After Treatment by Narrowband UVB Labelled (NB1, NB2) and After Treatment 
With Monochromatic Excimer Light (MEL 1, MEL 2). Vitiliginous areas (V1, V2) showed scattered perivascular lymphocytes (hollow 
arrows), clear basal cells (compact arrows) with moderate dermal edema. After treatment by NB UVB (NB1, NB2), showed similar findings 
especially the absence of basal melanocytes. While after treatment by MEL (MEL1, MEL2) some improvement was evident by appearance 
of pigmented basal melanocytes (stars) and less perivascular lymphocytes (hollow arrows) (H&E x 200).
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In our study, on the clinical level, repigmentation was 
detected in the macules treated with 308-nm MEL as early 
as the eighth session (fourth week) compared to those 
treated with NB-UVB. There was no superior significance 
to any treatment modality in regards to side effects, as 
also confirmed by Linthorst et al.11
Our results, however, did not match those of Verhaeghe 
et al,12 who led their study on 11 patients only, where 20% 
achieved repigmentation by NB-UVB after 24 sessions, 
while none achieved repigmentation by MEL.
To the best of our knowledge and up to date, there are 
no studies in literature comparing the histopathological 
correlation between MEL and NB-UVB in the treatment 
of vitiligo using H&E, and immunohistochemically using 
HMB-45 stain, as we did. Moosavi et al proposed the 
possibility of a relationship between the amount of HMB-
45 staining and the repigmentation rate in vitiligo patients 
and could not find such relation.13
Regarding H&E staining, there was superior statistical 
significance between MEL and NB UVB regarding basal 
membrane thickness, vacuolated keratinocytes, with basal 
pigmented cells being more evident in MEL treated areas.
No superiority in any modality regarding dermal 
edema and perivascular inflammation, lead to opening 
Figure 2. Biopsy Sample Before Treatment Labeled (V3, V4), After Treatment by Narrowband UVB Labelled (NB3, NB4) and After Treatment 
With Monochromatic Excimer Light (MEL 3, MEL 4). Vitiliginous areas (V3, V4) showed scattered perivascular lymphocytes (hollow arrows), 
clear basal cells (compact arrows) with moderate dermal edema. After treatment by NB-UVB (NB3, NB4) it showed similar findings, 
especially absence of basal melanocytes. While after treatment by MEL (MEL3, MEL4) some improvement was evident by appearance of 
pigmented basal melanocytes (stars) and less perivascular lymphocytes (hollow arrows) (H&E x200).
Figure 3. High Power View of the Skin of Before Treatment (V1,V2) Showing Complete Negative Staining of the Basal Cells for HMB45 (the 
hollow arrows ). Labeling Index (LI) = 0%. After treatment by Nb-UVB ( NB1,NB2) the biopsy sample did not show any positively stained 
basal cells for HMB-45 (hollow arrows) LI = 0%. After treatment by MEL (MEL1, MEL2) the slide showed scattered positive basal cells for 
HMB-45 (compact arrows). MEL 1 LI = 30.8%  MEL 2 LI = 50% (HMB-45 x400 [D: dermis, E: epidermis]).
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a discussion for the exact mechanism by which 
phototherapy treats vitiligo. Park et al suggested that the 
initiation of T-cell apoptosis is higher with (MEL) than 
with NB-UVB phototherapy.14
To conclude, NB-UVB is still the standard phototherapeutic 
treatment of choice for vitiligo. However, MEL has been 
recently established as a comparable active treatment 
option that encourages more repigmentation than NB-
UVB in relatively earlier sessions; these findings were 
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